YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT05767892 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: YK-209A tablet
DRUG: Pemetrexed+carboplatin/Cisplatin

Sponsor

Suzhou Puhe Pharmaceutical Technology Co., LTD